TNFSF13B and infection: However, a pan-B cell depletion approach to therapy renders a patient vulnerable to infections usually controlled by humoral immunity, so alternative approaches inhibiting B cells such as Obexelimab, a monoclonal antibody that binds to CD19 and FcyIIb (Phase 3 INDIGO), or targeting specific B cell pathways such as Bruton tyrosine kinase inhibitors and B cell activating factor (BAFF) inhibitors are also under investigation [22,23,24].